Use of Artificial Intelligence to Predict Complications Following Abdominal Aortic Surgery
NCT ID: NCT06884397
Last Updated: 2025-06-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
300 participants
OBSERVATIONAL
2025-04-14
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Role of Artificial Intelligence in the Treatment of Abdominal Aortic Aneurysms
NCT05643664
AI-enhanced Imaging Analysis to Predict Post-EVAR
NCT06592105
REGISTRY on the Implementation of Artificial Intelligence in the Automatic Analysis of Vascular Network Segmentation
NCT06451315
Prevention of Type II Endoleaks During Endovascular Treatment of Abdominal Aortic Aneurysm: Endovascular Treatment Versus Combination With Coil Embolisation of the Aneurysmal Sac
NCT01878240
Biomechanical and Microstructural Properties of Ascending Aortic Aneurysms
NCT03142074
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In France, the placement of abdominal aortic endoprosthesis (AAE) for treating infrarenal abdominal aortic aneurysm (AAA) follows the recommendations of the French National Authority for Health (HAS) from 2001, updated in 2009 in light of medical device developments and subsequent literature data (2000-2006). It specifically states that: "endovascular treatment is less invasive than surgical treatment, allowing for reduced 30-day morbidity rates for patients eligible for both surgery and endovascular treatment." Endovascular treatment can thus be offered to patients with normal surgical risk and favorable anatomical criteria, alongside surgical treatment, after informing the patient about the benefits and risks of both methods. The vast majority of patients with AAE require regular long-term follow-up, focusing on sac dimension and volume analysis and complication management. All patients must simultaneously receive optimal treatment for their vascular risk factors and comorbidities.
The updated recommendations can be summarized as follows:
* Indications for treating asymptomatic infrarenal AAAs: AAAs with greatest diameter \> 50 mm or diameter increase of more than 5 mm in six months and 10 mm in 1 year.
* A symptomatic or complicated AAA is treated regardless of size.
* Despite the absence of conclusive data, a saccular AAA is considered high-risk due to its particular morphology and is proposed for treatment even if its greatest diameter is \< 50 mm.
Since 2009, the number of endoprosthetic treatments has steadily increased at the expense of open procedures, although a medical-economic evaluation has questioned the efficiency of endovascular technique in patients eligible for both techniques. The long-term benefit in preventing mortality from AAA rupture remains unestablished (the mortality benefit difference is not maintained at 4 years), and even though most patients die from their comorbidities rather than their aneurysm, the first deaths from late rupture (beyond the fifth year of implantation) have appeared in long-term follow-up studies.
Concurrently, these studies have shown that nearly half of treated patients will require one or more additional procedures in subsequent years, and among treated patients:
* Only those showing aneurysmal sac shrinkage are considered cured.
* An average volume reduction of 3.2% would be sufficient to prevent endoleak occurrence.
* Conversely, a volume increase of more than 2% would be significantly associated with endoleak existence.
Endoleak is the most common complication after AAE placement, with incidence varying greatly depending on type and time elapsed since endoprosthesis placement. It is defined by blood circulation between the AAE and the arterial wall of the AAA. Five types of endoleak have been described according to anatomical, chronological, or physiological characteristics:
* Type I Endoleak: Ia) proximal anterograde peri-prosthetic flow due to endoprosthesis fixation failure, Ib) distal retrograde peri-prosthetic flow due to endoprosthesis fixation failure, Ic) iliac occluder seal failure,
* Type II Endoleak: retrograde flow from lumbar artery(ies) or inferior mesenteric artery feeding the aneurysmal sac: IIa) reperfusion through inferior mesenteric artery, IIb) reperfusion through lumbar artery(ies)
* Type III Endoleaks: IIIa) separation of modular endoprosthesis components, IIIb) fabric degradation. Endoleaks indicating early mechanical failure or premature fatigue of the endoprosthesis, potentially facilitated by AAA morphological changes, particularly its retraction
* Type IV Endoleaks: excessive endoprosthesis porosity. Generally early (\<30 days post-implantation), initially described but now almost non-existent due to fabric improvements
* Type V Endoleak: residual hyperpressure in the aneurysmal sac without obvious cause (no individualized leak) associated with AAA size increase. It warrants thorough investigation for endoleak and may lead to explantation.
Several teams have proposed preoperative criteria to predict endoleak risk (preoperative inferior mesenteric artery patency, sac size), but without real evidence. Some teams propose preventive embolizations based on these criteria (pre- or during procedure).
The investigators propose to evaluate whether a machine learning algorithm can predict endoleak risk from initial CT scan images.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient treated for an abdominal aortic aneurysm
Indications for infrarenal abdominal aortic aneurysm (AAA) treatment with abdominal aortic endoprosthesis (AAE) were :
* AAAs with greatest diameter \> 50 mm for women and \> 55 mm for men, or diameter increase of more than 5 mm in six months and 10 mm in 1 year.
* A symptomatic or complicated AAA is treated regardless of size.
* Despite the absence of conclusive data, a saccular AAA is considered high-risk due to its particular morphology and is proposed for treatment even if its greatest diameter is \< 50 mm.
Abdominal aortic endoprosthesis
An endoprosthesis consisting of a metal spring covered with an impermeable fabric is inserted through an artery and deployed inside the aorta.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Abdominal aortic endoprosthesis
An endoprosthesis consisting of a metal spring covered with an impermeable fabric is inserted through an artery and deployed inside the aorta.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Refuse the use of their data
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
La Rochelle University
UNKNOWN
Groupe Hospitalier de la Rochelle Ré Aunis
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sébastien Franco, MD
Role: STUDY_DIRECTOR
Groupe Hospitalier de la Rochelle Ré Aunis
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Groupe Hospitalier de la Rochelle Ré Aunis
La Rochelle, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Samura M, Morikage N, Otsuka R, Mizoguchi T, Takeuchi Y, Nagase T, Harada T, Yamashita O, Suehiro K, Hamano K. Endovascular Aneurysm Repair With Inferior Mesenteric Artery Embolization for Preventing Type II Endoleak: A Prospective Randomized Controlled Trial. Ann Surg. 2020 Feb;271(2):238-244. doi: 10.1097/SLA.0000000000003299.
Gentsu T, Yamaguchi M, Sasaki K, Kawasaki R, Horinouchi H, Fukuda T, Miyamoto N, Mori T, Sakamoto N, Uotani K, Taniguchi T, Koda Y, Yamanaka K, Takahashi H, Okada K, Hayashi T, Watanabe T, Nomura Y, Matsushiro K, Ueshima E, Okada T, Sugimoto K, Murakami T. Side branch embolization before endovascular abdominal aortic aneurysm repair to prevent type II endoleak: A prospective multicenter study. Diagn Interv Imaging. 2024 Sep;105(9):326-335. doi: 10.1016/j.diii.2024.03.003. Epub 2024 Mar 19.
Tinelli G, D'Oria M, Sica S, Mani K, Rancic Z, Resch TA, Beccia F, Azizzadeh A, Da Volta Ferreira MM, Gargiulo M, Lepidi S, Tshomba Y, Oderich GS, Haulon S; SLIM F-U EVAR, Collaborative Study Group. The sac evolution imaging follow-up after endovascular aortic repair: An international expert opinion-based Delphi consensus study. J Vasc Surg. 2024 Sep;80(3):937-945. doi: 10.1016/j.jvs.2024.03.007. Epub 2024 Mar 8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P01045
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.